S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
NYSE:EBS

Emergent BioSolutions - EBS Stock Forecast, Price & News

$13.47
+0.35 (+2.67%)
(As of 01/27/2023 08:54 PM ET)
Add
Compare
Today's Range
$13.06
$13.54
50-Day Range
$11.00
$13.94
52-Week Range
$10.61
$47.71
Volume
400,900 shs
Average Volume
820,100 shs
Market Capitalization
$671.99 million
P/E Ratio
17.27
Dividend Yield
N/A
Price Target
$36.75

Emergent BioSolutions MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
172.8% Upside
$36.75 Price Target
Short Interest
Bearish
13.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.40
Upright™ Environmental Score
News Sentiment
-0.31mentions of Emergent BioSolutions in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$22,829 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.61) to $0.38 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.63 out of 5 stars

Medical Sector

102nd out of 1,049 stocks

Pharmaceutical Preparations Industry

35th out of 514 stocks


EBS stock logo

About Emergent BioSolutions (NYSE:EBS) Stock

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Stock News Headlines

Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock? (EBS)
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Emergent BioSolutions Inc. (EBS)
Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates
See More Headlines
Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Company Calendar

Last Earnings
11/08/2022
Today
1/29/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
CUSIP
29089Q10
Employees
2,416
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$36.75
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+172.8%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$230.90 million
Pretax Margin
7.73%

Debt

Sales & Book Value

Annual Sales
$1.51 billion
Cash Flow
$8.42 per share
Book Value
$30.09 per share

Miscellaneous

Free Float
44,350,000
Market Cap
$671.99 million
Optionable
Optionable
Beta
0.89

Key Executives

  • Robert G. Kramer
    President, Chief Executive Officer & Director
  • Adam Robert Havey
    Chief Operating Officer & EVP-Business Operations
  • Richard Scott LindahlRichard Scott Lindahl
    Chief Financial Officer, Treasurer & Executive VP
  • Sharon M. Solomon
    Chief Information Officer & Senior Vice President
  • Christopher H. Cabell
    Chief Medical Officer & Head-Clinical Development













EBS Stock - Frequently Asked Questions

Should I buy or sell Emergent BioSolutions stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares.
View EBS analyst ratings
or view top-rated stocks.

What is Emergent BioSolutions' stock price forecast for 2023?

6 equities research analysts have issued 1-year price objectives for Emergent BioSolutions' stock. Their EBS share price forecasts range from $25.00 to $55.00. On average, they anticipate the company's stock price to reach $36.75 in the next year. This suggests a possible upside of 172.8% from the stock's current price.
View analysts price targets for EBS
or view top-rated stocks among Wall Street analysts.

How have EBS shares performed in 2023?

Emergent BioSolutions' stock was trading at $11.81 at the beginning of the year. Since then, EBS shares have increased by 14.1% and is now trading at $13.47.
View the best growth stocks for 2023 here
.

Are investors shorting Emergent BioSolutions?

Emergent BioSolutions saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 5,570,000 shares, an increase of 63.3% from the December 31st total of 3,410,000 shares. Based on an average daily trading volume, of 959,600 shares, the days-to-cover ratio is presently 5.8 days. Currently, 13.7% of the company's stock are short sold.
View Emergent BioSolutions' Short Interest
.

When is Emergent BioSolutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our EBS earnings forecast
.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) posted its earnings results on Tuesday, November, 8th. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.06) by $1.21. The biopharmaceutical company had revenue of $240 million for the quarter, compared to analyst estimates of $268.17 million. Emergent BioSolutions had a trailing twelve-month return on equity of 9.52% and a net margin of 3.54%.

What guidance has Emergent BioSolutions issued on next quarter's earnings?

Emergent BioSolutions updated its FY 2022 earnings guidance on Friday, January, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.10 billion-$1.12 billion, compared to the consensus revenue estimate of $1.09 billion.

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

What is Emergent BioSolutions' stock symbol?

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.12%), Strs Ohio (0.10%), Values First Advisors Inc. (0.07%), Yousif Capital Management LLC (0.05%), SummerHaven Investment Management LLC (0.05%) and Comerica Bank (0.05%). Insiders that own company stock include Adam Havey, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Richard S Lindahl, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
View institutional ownership trends
.

How do I buy shares of Emergent BioSolutions?

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Emergent BioSolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $13.47.

How much money does Emergent BioSolutions make?

Emergent BioSolutions (NYSE:EBS) has a market capitalization of $672.02 million and generates $1.79 billion in revenue each year. The biopharmaceutical company earns $230.90 million in net income (profit) each year or $0.78 on an earnings per share basis.

How many employees does Emergent BioSolutions have?

The company employs 2,416 workers across the globe.

How can I contact Emergent BioSolutions?

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The official website for the company is www.emergentbiosolutions.com. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at burrowsr@ebsi.com, or via fax at 301-795-1899.

This page (NYSE:EBS) was last updated on 1/30/2023 by MarketBeat.com Staff